Sun Pharma reports strong FY25 growth and robust pipeline

Sun Pharmaceutical Industries Limited reported strong financial performance for fiscal year 2025, with sales reaching Rs 520 bn, representing a 9% year-over-year increase. The company's adjusted net profit rose 19% to Rs 119.8 bn. EBITDA grew by 17% to Rs 152.7 bn, while operating cash flow increased by 21% over the FY10-FY25 period. R&D spend for FY25 was 6.2% of sales, totaling Rs 32.5 bn.

The company maintains a diversified revenue base, with US Formulations contributing 31% to FY25 sales (Rs 162.4 bn) and India Formulations accounting for 33% (Rs 169.2 bn). Innovative Medicines sales reached $1,216 mn in FY25, growing at a 23% CAGR since FY20, with Ilumya being the largest product at $681 mn. Sun Pharma is the largest pharma company in India, holding an 8.3% market share.

Key strategic initiatives include expanding innovative and complex product portfolios, strengthening global market presence, and maintaining leadership in sustainability. The company approved 548 ANDAs and 57 NDAs by H1FY26, with a pipeline of 117 ANDAs and 14 NDAs pending approval with USFDA. Global manufacturing spans 40 facilities across India, the Americas, Asia, Africa, Australia, and Europe.